Cargando…

What will be the role of molnupiravir in the treatment of COVID-19 infection?

Detalles Bibliográficos
Autores principales:	Vitiello, Antonio, Troiano, Valentina, La Porta, Raffaele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570236/ https://www.ncbi.nlm.nih.gov/pubmed/34754175 http://dx.doi.org/10.1007/s40267-021-00879-2

Ejemplares similares

COVID-19 vaccination in pregnancy
por: Vitiello, Antonio, et al.
Publicado: (2021)

Molnupiravir for COVID-19
Publicado: (2022)

Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?
por: Vitiello, Antonio, et al.
Publicado: (2021)

Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
por: Eloy, Philippine, et al.
Publicado: (2021)

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021)

COVID-19 vaccines and decreased transmission of SARS-CoV-2
por: Vitiello, A., et al.
Publicado: (2021)

Molnupiravir: A new candidate for COVID‐19 treatment
por: Pourkarim, Fariba, et al.
Publicado: (2021)

The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19
por: Cheng, Shih-Lung, et al.
Publicado: (2023)

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19
por: Vitiello, Antonio, et al.
Publicado: (2021)

Efficacy and safety of molnupiravir for COVID-19 patients
por: Fatima, Maurish, et al.
Publicado: (2022)

COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view
por: Vitiello, Antonio, et al.
Publicado: (2021)

Breakthrough COVID-19 Infections: What Are They and What Do They Look Like?
por: Elicker, Brett M.
Publicado: (2022)

Review on molnupiravir as a promising oral drug for the treatment of COVID-19
por: Zarenezhad, Elham, et al.
Publicado: (2022)

Molnupiravir as an Early Treatment for COVID-19: A Real Life Study
por: Pontolillo, Michela, et al.
Publicado: (2022)

What is the Performance and Role of CT in Suspected COVID-19 Infection?
por: Elicker, Brett M.
Publicado: (2020)

Molnupiravir in COVID-19: A systematic review of literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

Molnupiravir and Its Antiviral Activity Against COVID-19
por: Tian, Lili, et al.
Publicado: (2022)

Vascularite rétinienne post-Covid-19 et Molnupiravir
por: Lassouli, I., et al.
Publicado: (2022)

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
por: Yip, Ashley Jia Wen, et al.
Publicado: (2022)

PANORAMIC: important insights into molnupiravir use in COVID-19
por: Kidd, Michael R, et al.
Publicado: (2023)

On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
por: Boretti, Alberto
Publicado: (2023)

The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
por: Kamal, Lina, et al.
Publicado: (2022)

New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
por: Atmar, Robert L., et al.
Publicado: (2022)

(349) Molnupiravir vs Remdesivir for Treatment of Covid-19 in Lung Transplant Recipients
por: Razia, D., et al.
Publicado: (2023)

The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced
por: Vitiello, Antonio, et al.
Publicado: (2021)

NZ's Pharmac negotiates deal for molnupiravir to treat COVID-19
Publicado: (2021)

Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India
por: Sinha, Shubhadeep, et al.
Publicado: (2022)

Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
por: Chang, Yi-Chin, et al.
Publicado: (2023)

The effect of molnupiravir on post-acute outcome of COVID-19 survivors
por: Hsu, Wan-Hsuan, et al.
Publicado: (2023)

Nirmatrelvir and Molnupiravir and Post–COVID-19 Condition in Older Patients
por: Fung, Kin Wah, et al.
Publicado: (2023)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023)

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
por: Imran, Mohd., et al.
Publicado: (2021)

Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis
por: Benaicha, Karima, et al.
Publicado: (2023)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
por: Gentile, Ivan, et al.
Publicado: (2022)

COVID‐19 infection in CVID patients: What we know so far
por: Weifenbach, Niels, et al.
Publicado: (2021)

Molnupiravir — A Step toward Orally Bioavailable Therapies for Covid-19
por: Whitley, Richard
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u0mu84oddmmcehd2q9cis9ibur